I

mmunotherapy is a delicate balance: You have to rally a patient’s immune cells into action to kill diseased cells, but keep them away from healthy tissues. Vedantra Pharmaceuticals, a startup based in Cambridge, Mass., is working on a way to refine that process.

The company has developed next-gen nanoparticle vaccines — engineering vesicles that help ferry the therapy straight to the lymph nodes. That helps the body generate a stronger immune response. The work, based on research at MIT, is still preclinical, but Vedantra hopes it can be used to bolster cancer treatments. It’s focusing first on malignancies provoked by the HPV virus — such as cervical and head and neck cancer.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories